
Stefanos Theoharis, PhD
Extensive Cell and Gene Therapy Experience
Career Highlights
Stefanos Theoharis has over 20 years of extensive experience in the cell and gene therapy space, encompassing business development, program management, manufacturing, and basic research. He is currently the CEO of OneChain Immunotherapeutics, the largest CAR-T company in Spain, developing autologous and allogeneic CAR-T therapies for haematological malignancies and solid tumours. In this role, Stefanos works closely with clients in the CAR/TCR field and in vivo gene therapy, focusing on product development, licensing, and manufacturing strategies. His career highlights include serving as CBO at Bone Therapeutics, SVP of Corporate Development at Cell Medica (now Kuur Therapeutics), where he led strategic alliances with Baylor College of Medicine and University College London, acquired Delenex Therapeutics.
Previously, Stefanos was the Chief Business Officer at apceth, where he was responsible for business development and project management for the company’s contract development and manufacturing organization (CDMO) activities, now part of Hitachi Chemical Advanced Therapeutics Solutions, LLC and the company’s proprietary therapeutics platform, based on genetically modified mesenchymal stem cells (MSC). Additionally, Stefanos held the position of Director of Emerging Technologies Partnering at Roche, where he focused on partnering activities for emerging technologies and investment banking at Lazard. He obtained his OhD on gene therapy and immunology at Imperial College London. His broad expertise and leadership have significantly contributed to the advancement of cell and gene therapy, making him a key figure in the industry.
Education
-
PhD in gene therapy and immunology and postdoctoral research experience at Imperial College London
-
MSc in Molecular Medicine at Imperial College London